Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Shintaro Akiyama, Shadi Hamdeh, Dejan Micić, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 384-391
Open Access | Times Cited: 366

Showing 1-25 of 366 citing articles:

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld, Martin Schäfer, Milena Gianfrancesco, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 7, pp. 930-942
Open Access | Times Cited: 623
SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
Richard Conway, Alyssa Grimshaw, Maximilian F. Konig, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 5, pp. 766-775
Open Access | Times Cited: 158
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety
Nicoletta Luxi, Alexia Giovanazzi, Annalisa Capuano, et al.
Drug Safety (2021) Vol. 44, Iss. 12, pp. 1247-1269
Open Access | Times Cited: 124
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
Youn Ho Shin, Jae Il Shin, Sung Yong Moon, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e698-e706
Open Access | Times Cited: 116
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases
Rebecca Hasseli, Ulf Müeller-Ladner, Bimba F. Hoyer, et al.
RMD Open (2021) Vol. 7, Iss. 1, pp. e001464-e001464
Open Access | Times Cited: 112
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman, Philip C. Robinson, Thomas S. Uldrick, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002630-e002630
Open Access | Times Cited: 105
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 7, pp. e490-e506
Open Access | Times Cited: 92
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Manuel F. Ugarte‐Gil, Graciela S. Alarcón, Zara Izadi, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 970-978
Open Access | Times Cited: 79
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Joel M. Gelfand, April W. Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology (2021) Vol. 84, Iss. 5, pp. 1254-1268
Open Access | Times Cited: 97
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
Filippo Fagni, David Simón, Koray Taşçılar, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e724-e736
Open Access | Times Cited: 94
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 8, pp. 1086-1093
Open Access | Times Cited: 91
COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis
Kai Wei Lee, Sook Fan Yap, Yun Fong Ngeow, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 7, pp. 3554-3554
Open Access | Times Cited: 90
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
Ruth Fernandez‐Ruiz, Jacqueline L Paredes, Timothy B. Niewold
Translational research (2020) Vol. 232, pp. 13-36
Open Access | Times Cited: 88
Perspective of patients with autoimmune diseases on COVID-19 vaccination
Laura Boekel, Femke Hooijberg, Zoé L.E. van Kempen, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 4, pp. e241-e243
Open Access | Times Cited: 87
Vitamin D deficiency: concern for rheumatoid arthritis and COVID-19?
Sneha Verma, Ved Chaturvedi, N K Ganguly, et al.
Molecular and Cellular Biochemistry (2021) Vol. 476, Iss. 12, pp. 4351-4362
Open Access | Times Cited: 85
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review
Peter C. Taylor, Fabiola Atzeni, Alejandro Balsa, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 509-509
Open Access | Times Cited: 76
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study
Éric Goffin, Alexandre Candellier, Priya Vart, et al.
Nephrology Dialysis Transplantation (2021) Vol. 36, Iss. 11, pp. 2094-2105
Open Access | Times Cited: 75
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
Matteo Piga, Laurent Arnaud
Journal of Clinical Medicine (2021) Vol. 10, Iss. 2, pp. 243-243
Open Access | Times Cited: 74
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
Cláudia Diniz Lopes Marques, Adriana María Kakehasi, Marcelo Medeiros Pinheiro, et al.
RMD Open (2021) Vol. 7, Iss. 1, pp. e001461-e001461
Open Access | Times Cited: 68
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data
Chuanhui Xu, Zixi Yi, Ruyi Cai, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 4, pp. 102778-102778
Open Access | Times Cited: 67
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Michel Obéid, Madeleine Suffiotti, Céline Pellaton, et al.
JAMA Oncology (2022) Vol. 8, Iss. 5, pp. e220446-e220446
Open Access | Times Cited: 62
Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning
Yvonne M. Mueller, Thijs J. Schrama, Rik Ruijten, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
C. Sieiro Santos, Sara Calleja Antolín, Clara Moriano Morales, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e001898-e001898
Open Access | Times Cited: 48
Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data
Ian C. Scott, Rebecca Whittle, James Bailey, et al.
The Lancet Regional Health - Europe (2022) Vol. 23, pp. 100519-100519
Open Access | Times Cited: 46
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
Roya Monica Dayam, Jaclyn C. Law, Rogier Goetgebuer, et al.
JCI Insight (2022) Vol. 7, Iss. 11
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top